Crohn’s Disease – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Adult Crohn’s Disease (US) 2022

Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and maintain remission. Treatment of adult CD typically begins with safe, albeit less-efficacious, conventional agents (e.g., 5-ASAs) but often progresses to more-potent drugs, such as immunosuppressants and/or biologics. However, this scenario is changing, and more physicians are prescribing biologics as first-line therapy for recently diagnosed CD. Among the biologics, TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) have a relatively constant patient share; however, non-TNF biologics (e.g., Takeda’s Entyvio, Janssen’s Stelara) have experienced a sharp increase in patient share. This content provides manufacturers of current CD treatments and developers of novel CD agents with insights into the use of these drugs and into the market trends in the CD space.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult CD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult CD patients?
  • How have Entyvio and Stelara been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of adult CD patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of adult CD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: Janssen, AbbVie, Takeda, UCB

Key drugs: Humira, Remicade, Entyvio, Stelara, Cimzia, biosimilar infliximab, aminosalicylates, immunosuppressants

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Table of contents

  • Crohn's Disease - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Adult Crohn's Disease (US) 2022
    • Treatment Algorithms: Claims Data Analysis Crohn's Disease (Adult) US February 2022
    • Treatment Algorithms: Claims Data Analysis Crohn's Disease (Adult) US 2022 Dashboard

launch Related Market Assessment Reports